Prodways Group Progresses in Strategic Divestment with DeltaMed Sale

Prodways Group announced an agreement to sell its subsidiary, DeltaMed, as part of a strategic shift. The €10.25 million transaction is aimed at divesting the Materials business and aligns with the group's 2025 strategy to reconfigure its Systems division. The sale requires approval from Prodways Group's General Meeting of shareholders scheduled for December 2, 2026.

DeltaMed, specializing in materials for dental and additive manufacturing sectors, generates an annual EBITDA of approximately €1.6 million. This move follows the recent sale of Prodways' Software business, underscoring the company's focus on refining its operations. The sale is expected to benefit Prodways shareholders, with a portion of proceeds possibly distributed pending approval in the upcoming financial meeting.

The acquisition positions DeltaMed in a dental-focused group, enhancing its growth prospects and aligning more closely with its market demands.